Moderna reports third quarter revenue of $1.0 billion and net loss of $0.2 billion

Reuters

11/06

<a href="https://laohu8.com/S/MRNA">Moderna</a> reports third quarter revenue of $1.0 billion and net loss of $0.2 billion

Moderna Inc. reported third quarter 2025 revenue of $1.0 billion, with a GAAP net loss of $0.2 billion and GAAP earnings per share of $(0.51). The company narrowed its projected 2025 revenue range to $1.6-$2.0 billion, reduced expected 2025 GAAP operating expenses to $5.2-$5.4 billion, and increased its expected year-end cash balance to $6.5-$7.0 billion. COVID vaccine sales for the third quarter totaled $971 million, including $781 million in the U.S. and $190 million internationally. The company received FDA approval for its 2025-2026 mNEXSPIKE COVID vaccine for adults aged 65 and older and certain younger individuals with risk factors, with approvals also granted in Canada and filings in other regions. Capital expenditures for 2025 are expected to be approximately $0.3 billion. Moderna also presented Phase 3 data for its seasonal flu vaccine and plans to complete regulatory submissions by January 2026 in several countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001682852-25-000073), on November 06, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581624750"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581624750\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581624750?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581624750","market":"fut","top_or_hot":-1,"title":"Moderna reports third quarter revenue of $1.0 billion and net loss of $0.2 billion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> reports third quarter revenue of $1.0 billion and net loss of $0.2 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Moderna Inc. reported third quarter 2025 revenue of $1.0 billion, with a GAAP net loss of $0.2 billion and GAAP earnings per share of $(0.51). The company narrowed its projected 2025 revenue range to $1.6-$2.0 billion, reduced expected 2025 GAAP operating expenses to $5.2-$5.4 billion, and increased its expected year-end cash balance to $6.5-$7.0 billion. COVID vaccine sales for the third quarter totaled $971 million, including $781 million in the U.S. and $190 million internationally. The company received FDA approval for its 2025-2026 mNEXSPIKE COVID vaccine for adults aged 65 and older and certain younger individuals with risk factors, with approvals also granted in Canada and filings in other regions. Capital expenditures for 2025 are expected to be approximately $0.3 billion. Moderna also presented Phase 3 data for its seasonal flu vaccine and plans to complete regulatory submissions by January 2026 in several countries.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001682852-25-000073), on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna reports third quarter revenue of $1.0 billion and net loss of $0.2 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna reports third quarter revenue of $1.0 billion and net loss of $0.2 billion\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-06 20:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> reports third quarter revenue of $1.0 billion and net loss of $0.2 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Moderna Inc. reported third quarter 2025 revenue of $1.0 billion, with a GAAP net loss of $0.2 billion and GAAP earnings per share of $(0.51). The company narrowed its projected 2025 revenue range to $1.6-$2.0 billion, reduced expected 2025 GAAP operating expenses to $5.2-$5.4 billion, and increased its expected year-end cash balance to $6.5-$7.0 billion. COVID vaccine sales for the third quarter totaled $971 million, including $781 million in the U.S. and $190 million internationally. The company received FDA approval for its 2025-2026 mNEXSPIKE COVID vaccine for adults aged 65 and older and certain younger individuals with risk factors, with approvals also granted in Canada and filings in other regions. Capital expenditures for 2025 are expected to be approximately $0.3 billion. Moderna also presented Phase 3 data for its seasonal flu vaccine and plans to complete regulatory submissions by January 2026 in several countries.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001682852-25-000073), on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL8pCwBT:1","article_id":"2581624750","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581624750","pubTimestamp":1762430704,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Moderna Inc. reported third quarter 2025 revenue of $1.0 billion, with a GAAP net loss of $0.2 billion and GAAP earnings per share of $. The company narrowed its projected 2025 revenue range to $1.6-$2.0 billion, reduced expected 2025 GAAP operating expenses to $5.2-$5.4 billion, and increased its expected year-end cash balance to $6.5-$7.0 billion. COVID vaccine sales for the third quarter totaled $971 million, including $781 million in the U.S. and $190 million internationally. The company received FDA approval for its 2025-2026 mNEXSPIKE COVID vaccine for adults aged 65 and older and certain younger individuals with risk factors, with approvals also granted in Canada and filings in other regions. Capital expenditures for 2025 are expected to be approximately $0.3 billion. Moderna also presented Phase 3 data for its seasonal flu vaccine and plans to complete regulatory submissions by January 2026 in several countries.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4501":"段永平概念","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念"},"translate_title":"Moderna报告第三季度营收10亿美元，净亏损2亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Moderna reports third quarter revenue of $1.0 billion and net loss of $0.2 billion\n    \n\n        Moderna Inc. reported third quarter 2025 revenue of $1.0 billion, with a GAAP net loss of $0.2 billion and GAAP earnings per share of $(0.51). The company narrowed its projected 2025 revenue range to $1.6-$2.0 billion, reduced expected 2025 GAAP operating expenses to $5.2-$5.4 billion, and increased its expected year-end cash balance to $6.5-$7.0 billion. COVID vaccine sales for the third quarter totaled $971 million, including $781 million in the U.S. and $190 million internationally. The company received FDA approval for its 2025-2026 mNEXSPIKE COVID vaccine for adults aged 65 and older and certain younger individuals with risk factors, with approvals also granted in Canada and filings in other regions. Capital expenditures for 2025 are expected to be approximately $0.3 billion. Moderna also presented Phase 3 data for its seasonal flu vaccine and plans to complete regulatory submissions by January 2026 in several countries.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001682852-25-000073), on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}